Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose
- PMID: 9096095
- DOI: 10.1007/BF00881816
Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose
Abstract
Use of iodine-123-alpha-methyl tyrosine (123I-IMT) allows investigation of the amino acid transport rate in gliomas. It was the aim of this study to compare the value of measurement of glucose metabolism with that of measurement of 123I-IMT uptake for the non-invasive grading of brain tumours. The study population comprised 23 patients with histopathologically proven primary brain tumours; 14 had high-grade gliomas, and nine low-grade brain neoplasms. Glucose metabolism was studied using an ECAT EXACT 47 positron emission tomography (PET) camera and fluorine-18 fluorodeoxyglucose (18F-FDG); 123I-IMT uptake was measured with the triple-headed single-photon emission tomography (SPET) camera, MULTISPECT 3. 18F-FDG and 123I-IMT uptake was quantified as ratios between the uptake by the tumour and contralateral regions of reference. Glucose metabolism and amino acid uptake of the brain tumours correlated significantly (r=0.71, P <0.001). Assuming discrimination thresholds between high-grade and low-grade tumours of 0.8 for 18F-FDG uptake and 1.8 for 123I-IMT uptake, the accuracy values of 18F-FDG PET and 123I-IMT SPET for differentiating between high-grade and low-grade tumours were 21/23 (91%) and 19/23 (83%), respectively. The difference in diagnostic performance was not significant on receiver operating characteristic analysis (P >0.4). It is concluded that there is no major difference between the PET investigation of glucose metabolism and the less expensive SPET measurement of amino acid uptake in terms of their accuracy in evaluating the malignancy grade of primary brain tumours. This encourages the performance of further studies to analyse the potential impact of 123I-IMT SPET on the therapeutic management of patients with brain tumours.
Similar articles
-
Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.Eur J Nucl Med. 1999 Feb;26(2):144-51. doi: 10.1007/s002590050370. Eur J Nucl Med. 1999. PMID: 9933348
-
Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.J Nucl Med. 1997 May;38(5):802-8. J Nucl Med. 1997. PMID: 9170450
-
3-[123I]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis.Eur J Nucl Med. 2001 Jul;28(7):855-61. doi: 10.1007/s002590100553. Eur J Nucl Med. 2001. PMID: 11504082
-
[Evaluation of brain tumors using positron emission tomography].Radiologe. 1992 Jun;32(6):282-9. Radiologe. 1992. PMID: 1322547 Review. German.
-
Imaging gliomas with positron emission tomography and single-photon emission computed tomography.Semin Nucl Med. 2003 Apr;33(2):148-62. doi: 10.1053/snuc.2003.127304. Semin Nucl Med. 2003. PMID: 12756647 Review.
Cited by
-
O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9. doi: 10.1007/s00259-004-1705-8. Epub 2005 Jan 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15650870 Clinical Trial.
-
Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and 18F-FDG-PET and the combined application of multiple models.Sci Rep. 2022 Apr 6;12(1):5722. doi: 10.1038/s41598-022-09803-8. Sci Rep. 2022. PMID: 35388124 Free PMC article.
-
123I-IMT SPET: introducing another research tool into clinical neuro-oncology?Eur J Nucl Med. 2001 Jan;28(1):1-4. doi: 10.1007/s002590000352. Eur J Nucl Med. 2001. PMID: 11202443 Review. No abstract available.
-
Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas.Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):24-31. doi: 10.1007/s00259-007-0514-2. Epub 2007 Sep 11. Eur J Nucl Med Mol Imaging. 2008. PMID: 17846769 Clinical Trial.
-
Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2344-53. doi: 10.1007/s00259-010-1572-4. Epub 2010 Jul 30. Eur J Nucl Med Mol Imaging. 2010. PMID: 20676638
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical